tiprankstipranks
Trending News
More News >

Alvotech’s Successful Nasdaq Stockholm Listing and Strategic Expansion

Story Highlights
  • Alvotech’s offering of SDRs on Nasdaq Stockholm was oversubscribed, gaining over 3,000 new shareholders.
  • Alvotech’s acquisition of Xbrane Biopharma’s R&D operations strengthens its scientific capabilities and growth strategy.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Alvotech’s Successful Nasdaq Stockholm Listing and Strategic Expansion

Confident Investing Starts Here:

The latest announcement is out from Alvotech ( (ALVO) ).

On May 16, 2025, Alvotech announced the successful outcome of its offering of Swedish Depository Receipts (SDRs) in connection with its listing on Nasdaq Stockholm, which was oversubscribed and attracted over 3,000 new shareholders. The listing is expected to enhance Alvotech’s market presence in the Nordic and European regions, improve access to capital, and attract a broader investor base. Additionally, Alvotech has acquired Xbrane Biopharma’s R&D operations in Sweden, which will bolster its scientific capabilities and support its growth strategy.

The most recent analyst rating on (ALVO) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.

Spark’s Take on ALVO Stock

According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.

Alvotech’s stock is rated moderately due to strong revenue growth and improved profitability offset by financial instability and cash flow concerns. Positive technical indicators and promising earnings guidance enhance the outlook, but valuation is moderate, and competitive pressures remain a risk.

To see Spark’s full report on ALVO stock, click here.

More about Alvotech

Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines. The company aims to be a leader in the biosimilar space by offering high-quality, cost-effective products through a fully integrated approach. Alvotech has a diverse pipeline targeting various diseases and has formed strategic partnerships to expand its reach across multiple global markets.

Average Trading Volume: 164,525

Technical Sentiment Signal: Sell

Current Market Cap: $3.1B

Learn more about ALVO stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App